Bainco International Investors lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.7% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 107,591 shares of the company’s stock after selling 2,930 shares during the quarter. Johnson & Johnson comprises 2.2% of Bainco International Investors’ portfolio, making the stock its 9th largest position. Bainco International Investors’ holdings in Johnson & Johnson were worth $13,920,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Virtus ETF Advisers LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $25,000. Krane Funds Advisors LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $26,000. Financial Advantage Inc. acquired a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $28,000. Crewe Advisors LLC increased its position in Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after acquiring an additional 196 shares during the period. Finally, Eii Capital Management Inc. acquired a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $39,000. Hedge funds and other institutional investors own 72.25% of the company’s stock.

Shares of NYSE JNJ opened at $133.00 on Friday. The stock has a fifty day moving average price of $130.83 and a two-hundred day moving average price of $134.05. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. The firm has a market cap of $343.25 billion, a P/E ratio of 16.26, a PEG ratio of 2.20 and a beta of 0.69. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.00 by $0.12. The firm had revenue of $20.73 billion during the quarter, compared to analyst estimates of $20.14 billion. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the company posted $2.05 EPS. On average, research analysts predict that Johnson & Johnson will post 8.65 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s payout ratio is currently 46.45%.

Several analysts recently commented on JNJ shares. Bank of America restated a “hold” rating and issued a $150.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Morgan Stanley restated an “equal weight” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Atlantic Securities upgraded Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Finally, Raymond James lowered their target price on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $151.64.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What is a dividend reinvestment plan?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.